China Universal Asset Management Co. Ltd. Has $4.14 Million Holdings in Biogen Inc. $BIIB

China Universal Asset Management Co. Ltd. lessened its holdings in Biogen Inc. (NASDAQ:BIIB) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,570 shares of the biotechnology company’s stock after selling 3,187 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Biogen were worth $4,142,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Biogen during the second quarter worth about $284,358,000. Orion Porfolio Solutions LLC increased its holdings in Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after acquiring an additional 509,809 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Biogen by 190.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after acquiring an additional 409,591 shares during the last quarter. AustralianSuper Pty Ltd increased its stake in shares of Biogen by 85.9% in the second quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock worth $92,863,000 after buying an additional 341,719 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Biogen by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after purchasing an additional 257,812 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BIIB. BMO Capital Markets boosted their target price on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Oppenheimer boosted their price target on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. Truist Financial lifted their price objective on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday, February 9th. TD Cowen boosted their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, Wells Fargo & Company raised their price target on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Sunday, February 8th. Twelve investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $205.04.

Biogen Trading Down 1.1%

Shares of NASDAQ BIIB opened at $192.08 on Friday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The business’s 50 day moving average price is $179.66 and its 200-day moving average price is $160.68. The company has a market cap of $28.19 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.54 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the business earned $3.44 EPS. The company’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.